HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP
- PMID: 17207708
- PMCID: PMC2527859
- DOI: 10.1016/j.humimm.2006.10.003
HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP
Abstract
This report describes the design of the eplet version of HLAMatchmaker to determine class II compatibility at the structural level. This matching algorithm is based on the hypothesis, developed from molecular modeling of crystallized antigen-antibody complexes, that functional epitopes are represented by patches of surface-exposed nonself-amino acid residues surrounded by residues within a 3-A radius. Patch determinations with a molecular viewer of crystalline structural models downloaded from the Entrez Molecular Modeling Database Web site led to the identification of 44 DRB, 33DQB, 29 DQA, 20 DPB, and 9 DPA unique combinations of polymorphic positions. The residue compositions of these patches were then determined from amino acid sequences. This analysis resulted in a repertoire of 146 DRB, 74 DQB, 58 DQA, 45 DPB, and 19 DPA eplets. In many eplets, the residues are in short linear sequences, but many other eplets have discontinuous sequences of residues that cluster on or near the molecular surface. This analysis has also shown that all serologically defined DR and DQ antigens detectable by monospecific antibodies have unique eplets. Other eplets are present in groups of class II antigens, many of which appear as cross-reacting. The eplet version of HLAMatchmaker should be considered as a hypothetical model for the structural assessment of donor-recipient compatibility and the determination of mismatch acceptability for sensitized patients. This computer algorithm can be downloaded from the HLA Matchmaker Webside at http://tpis.upmc.edu.
Figures
Similar articles
-
Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.Transpl Immunol. 2008 Feb;18(4):352-60. doi: 10.1016/j.trim.2007.10.001. Epub 2007 Oct 30. Transpl Immunol. 2008. PMID: 18158123 Free PMC article.
-
Correlations between Terasaki's HLA class II epitopes and HLAMatchmaker-defined eplets on HLA-DR and -DQ antigens.Tissue Antigens. 2009 Aug;74(2):134-46. doi: 10.1111/j.1399-0039.2009.01272.x. Epub 2009 Jun 2. Tissue Antigens. 2009. PMID: 19497040
-
A structurally based approach to determine HLA compatibility at the humoral immune level.Hum Immunol. 2006 Nov;67(11):847-62. doi: 10.1016/j.humimm.2006.08.001. Epub 2006 Sep 1. Hum Immunol. 2006. PMID: 17145365 Free PMC article.
-
Matchmaker, matchmaker make me a match: Opportunities and challenges in optimizing compatibility of HLA eplets in transplantation.Int J Immunogenet. 2021 Apr;48(2):135-144. doi: 10.1111/iji.12525. Epub 2021 Jan 10. Int J Immunogenet. 2021. PMID: 33426788 Review.
-
Are We Ready for Epitope-Based HLA Matching in Clinical Organ Transplantation?Transplantation. 2017 Aug;101(8):1755-1765. doi: 10.1097/TP.0000000000001667. Transplantation. 2017. PMID: 28207632 Review.
Cited by
-
HLA Amino Acid Polymorphisms and Kidney Allograft Survival.Transplantation. 2017 May;101(5):e170-e177. doi: 10.1097/TP.0000000000001670. Transplantation. 2017. PMID: 28221244 Free PMC article.
-
An Approach to Identify HLA Class II Immunogenic Epitopes in the Greek Population through Machine Learning Algorithms.J Clin Med. 2022 Nov 29;11(23):7046. doi: 10.3390/jcm11237046. J Clin Med. 2022. PMID: 36498621 Free PMC article.
-
Effects of immunotherapy induction on outcome and graft survival of kidney-transplanted patients with different immunological risk of rejection.BMC Nephrol. 2019 Aug 13;20(1):314. doi: 10.1186/s12882-019-1497-5. BMC Nephrol. 2019. PMID: 31409321 Free PMC article.
-
HLA-DQ-Specific Recombinant Human Monoclonal Antibodies Allow for In-Depth Analysis of HLA-DQ Epitopes.Front Immunol. 2022 Jan 7;12:761893. doi: 10.3389/fimmu.2021.761893. eCollection 2021. Front Immunol. 2022. PMID: 35069533 Free PMC article.
-
Anti-Human Leukocyte Antigen Antibody Detection from Terasaki's Humoral Theory to Delisting Strategies in 2024.Int J Mol Sci. 2025 Jan 13;26(2):630. doi: 10.3390/ijms26020630. Int J Mol Sci. 2025. PMID: 39859344 Free PMC article. Review.
References
-
- Schoenemann C, Groth J, Leverenz S, May G. HLA class I and class II antibodies: monitoring before and after kidney transplantation. Transplantation. 1998;65:1519. - PubMed
-
- Mahoney RJ, Taranto S, Edwards E. B-Cell Crossmatching and kidney allograft outcome in 9031 United States transplant recipients. Hum Immunol. 2002;63:324. - PubMed
-
- Gebel H, Bray R, Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk Amer J Transplant. 2003;3:1488. - PubMed
-
- Iniotaki-Theodoraki AG, Boletis JN, Trigas G, Kalogeropoulou HG, Kostakis AG, Stavropoulos-Giokas CG. Humoral immune reactivity against human leukocyte antigen (HLA)-DQ graft molecules in the early posttransplantation period. Transplantation. 2003;75:1601. - PubMed
-
- Itescu S, Tung TC, Burke EM, Weinberg A, Moazami N, Artrip JH, Suciu-Foca N, Rose EA, Oz MC, Michler RE. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation. 1998;98:786. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials